Investors
Invest in InDex
Pharmaceuticals
-
InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023
November 28, 2023 Regulatory
-
InDex Pharmaceuticals discontinues cobitolimod phase III program
November 21, 2023 Regulatory
InDex Pharmaceuticals published the interim report for Q3 2023 on November 28, 2023.
InDex Pharmaceuticals in numbers
-
15-30
The most common age of an ulcerative colitis diagnosis
-
2 Million
Patients living with ulcerative colitis in the US and Europe
-
7.5 billion USD
Total yearly sales of medications for ulcerative colitis
-
12 billion USD
The estimated total yearly sales of medication for ulcerative colitis in 2026
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.
Investor contact
